| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:50 UTC |
|---|
| Update Date | 2022-03-07 02:51:48 UTC |
|---|
| HMDB ID | HMDB0014972 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Mifepristone |
|---|
| Description | A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. [PubChem] |
|---|
| Structure | [H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H] InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 11-(4-DIMETHYLAMINO-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodec ahydro-cyclopenta[a]phenanthren-3-one | ChEBI | | Corlux | ChEBI | | Mifegyne | ChEBI | | Mifeprex | ChEBI | | Mifepristona | ChEBI | | Mifepristonum | ChEBI | | RU-486 | ChEBI | | RU486 | ChEBI | | Korlym | Kegg | | Mifepriston | HMDB | | Mifepristone exelgyn brand | HMDB | | Mifepristone contragest brand | HMDB | | Mifepristone danco brand | HMDB | | Contragest brand OF mifepristone | HMDB | | Danco brand OF mifepristone | HMDB | | Exelgyn brand OF mifepristone | HMDB | | Mifégyne | HMDB |
|
|---|
| Chemical Formula | C29H35NO2 |
|---|
| Average Molecular Weight | 429.5937 |
|---|
| Monoisotopic Molecular Weight | 429.266779369 |
|---|
| IUPAC Name | (10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-5-one |
|---|
| Traditional Name | (10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-5-one |
|---|
| CAS Registry Number | 84371-65-3 |
|---|
| SMILES | [H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H] |
|---|
| InChI Identifier | InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1 |
|---|
| InChI Key | VKHAHZOOUSRJNA-GCNJZUOMSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as oxosteroids. These are steroid derivatives carrying a C=O group attached to steroid skeleton. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Steroids and steroid derivatives |
|---|
| Sub Class | Oxosteroids |
|---|
| Direct Parent | Oxosteroids |
|---|
| Alternative Parents | |
|---|
| Substituents | - 3-oxosteroid
- Hydroxysteroid
- Oxosteroid
- 17-hydroxysteroid
- Tertiary aliphatic/aromatic amine
- Dialkylarylamine
- Aniline or substituted anilines
- Cyclohexenone
- Benzenoid
- Monocyclic benzene moiety
- Ynone
- Cyclic alcohol
- Tertiary alcohol
- Cyclic ketone
- Tertiary amine
- Ketone
- Alcohol
- Organooxygen compound
- Organonitrogen compound
- Organopnictogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Carbonyl group
- Organic oxide
- Amine
- Hydrocarbon derivative
- Aromatic homopolycyclic compound
|
|---|
| Molecular Framework | Aromatic homopolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 191 - 196 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.0034 g/L | Not Available | | LogP | 4.5 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 8.15 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 17.0545 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.36 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 42.7 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2686.1 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 293.6 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 249.2 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 178.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 160.4 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 772.7 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 702.5 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 145.8 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1649.9 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 500.7 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1474.1 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 525.8 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 388.5 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 326.4 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 546.1 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.4 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Mifepristone,1TMS,isomer #1 | CC#C[C@]1(O[Si](C)(C)C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](C3=CC=C(N(C)C)C=C3)C[C@@]21C | 3947.7 | Semi standard non polar | 33892256 | | Mifepristone,1TMS,isomer #2 | CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CCC4=C3[C@@H](C3=CC=C(N(C)C)C=C3)C[C@@]21C | 3895.7 | Semi standard non polar | 33892256 | | Mifepristone,2TMS,isomer #1 | CC#C[C@]1(O[Si](C)(C)C)CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CCC4=C3[C@@H](C3=CC=C(N(C)C)C=C3)C[C@@]21C | 3915.0 | Semi standard non polar | 33892256 | | Mifepristone,2TMS,isomer #1 | CC#C[C@]1(O[Si](C)(C)C)CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CCC4=C3[C@@H](C3=CC=C(N(C)C)C=C3)C[C@@]21C | 3875.7 | Standard non polar | 33892256 | | Mifepristone,2TMS,isomer #1 | CC#C[C@]1(O[Si](C)(C)C)CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CCC4=C3[C@@H](C3=CC=C(N(C)C)C=C3)C[C@@]21C | 4158.9 | Standard polar | 33892256 | | Mifepristone,1TBDMS,isomer #1 | CC#C[C@]1(O[Si](C)(C)C(C)(C)C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](C3=CC=C(N(C)C)C=C3)C[C@@]21C | 4215.8 | Semi standard non polar | 33892256 | | Mifepristone,1TBDMS,isomer #2 | CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CCC4=C3[C@@H](C3=CC=C(N(C)C)C=C3)C[C@@]21C | 4159.6 | Semi standard non polar | 33892256 | | Mifepristone,2TBDMS,isomer #1 | CC#C[C@]1(O[Si](C)(C)C(C)(C)C)CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CCC4=C3[C@@H](C3=CC=C(N(C)C)C=C3)C[C@@]21C | 4412.0 | Semi standard non polar | 33892256 | | Mifepristone,2TBDMS,isomer #1 | CC#C[C@]1(O[Si](C)(C)C(C)(C)C)CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CCC4=C3[C@@H](C3=CC=C(N(C)C)C=C3)C[C@@]21C | 4360.8 | Standard non polar | 33892256 | | Mifepristone,2TBDMS,isomer #1 | CC#C[C@]1(O[Si](C)(C)C(C)(C)C)CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CCC4=C3[C@@H](C3=CC=C(N(C)C)C=C3)C[C@@]21C | 4306.2 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Mifepristone GC-MS (Non-derivatized) - 70eV, Positive | splash10-0w29-0356900000-2d8af6b9cc4537ce26fd | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Mifepristone GC-MS (1 TMS) - 70eV, Positive | splash10-0079-2055900000-6e525ae464b1871d9ebe | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Mifepristone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Mifepristone , positive-QTOF | splash10-001i-0332900000-9cbfa7fe6866f246577a | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Mifepristone , positive-QTOF | splash10-008i-2952100000-aec78774f54c2156c662 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Mifepristone 45V, Positive-QTOF | splash10-008i-0931000000-ee8279dfb415bc0681f0 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Mifepristone 90V, Positive-QTOF | splash10-05qc-2920000000-0d03d8c581f1c4499042 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Mifepristone 60V, Positive-QTOF | splash10-001i-1930000000-99d6acb871669431c089 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Mifepristone 75V, Positive-QTOF | splash10-003r-1920000000-303a5d8b0036258c0881 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Mifepristone 15V, Positive-QTOF | splash10-001i-0000900000-7e417e2be2da168b3821 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Mifepristone 35V, Positive-QTOF | splash10-0089-0964600000-5ddcf4202f05b45619f4 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Mifepristone 30V, Positive-QTOF | splash10-0089-0953300000-18649aead8226d5457ec | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Mifepristone 45V, Positive-QTOF | splash10-008i-0931000000-6b177a9fd1b11cda4eee | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Mifepristone 90V, Positive-QTOF | splash10-05qc-2920000000-d4339450b67349c7406c | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Mifepristone 30V, Positive-QTOF | splash10-0089-0953300000-3040f97a5bcf7379d742 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Mifepristone 60V, Positive-QTOF | splash10-001i-1930000000-75e712433c777112ab39 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mifepristone 10V, Positive-QTOF | splash10-001i-0003900000-482e952a320026611e1a | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mifepristone 20V, Positive-QTOF | splash10-0il0-0019500000-0f2300ca0d9d68333f18 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mifepristone 40V, Positive-QTOF | splash10-006y-0239000000-3062d0e76d145ad51502 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mifepristone 10V, Negative-QTOF | splash10-004i-0000900000-2424eebcdaf0cba228cb | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mifepristone 20V, Negative-QTOF | splash10-004i-1003900000-0d5db361e6c6078d19c6 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mifepristone 40V, Negative-QTOF | splash10-0ir9-1209300000-533594d69ffd57a0e51a | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mifepristone 10V, Positive-QTOF | splash10-001i-0000900000-8a86e41d44598870ec34 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mifepristone 20V, Positive-QTOF | splash10-001i-0245900000-5a92d3450ccf91b2fea2 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mifepristone 40V, Positive-QTOF | splash10-000t-2419000000-7daab3ac34340f53f4f6 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mifepristone 10V, Negative-QTOF | splash10-004i-0000900000-a4eb2582acf4a0d738a0 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mifepristone 20V, Negative-QTOF | splash10-004i-0001900000-5e48687bc755905f2a3d | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mifepristone 40V, Negative-QTOF | splash10-0gbc-0179400000-0a9aad20761af0cfe7fa | 2021-10-11 | Wishart Lab | View Spectrum |
NMR Spectra| Spectrum Type | Description | Deposition Date | Source | View |
|---|
|
|---|
| General References | - Spitz IM, Bardin CW, Benton L, Robbins A: Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med. 1998 Apr 30;338(18):1241-7. [PubMed:9562577 ]
- Heikinheimo O, Kekkonen R, Lahteenmaki P: The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Contraception. 2003 Dec;68(6):421-6. [PubMed:14698071 ]
- Piaggio G, von Hertzen H, Heng Z, Bilian X, Cheng L: Meta-analyses of randomized trials comparing different doses of mifepristone in emergency contraception. Contraception. 2003 Dec;68(6):447-52. [PubMed:14698075 ]
- Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM: Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005 May-Jun;11(3):293-307. Epub 2005 Mar 24. [PubMed:15790602 ]
- Fiala C, Gemzel-Danielsson K: Review of medical abortion using mifepristone in combination with a prostaglandin analogue. Contraception. 2006 Jul;74(1):66-86. Epub 2006 May 19. [PubMed:16781264 ]
- Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9. [PubMed:11413487 ]
- Watson AD: Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res. 2006 Oct;47(10):2101-11. Epub 2006 Aug 10. [PubMed:16902246 ]
- Sethi JK, Vidal-Puig AJ: Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007 Jun;48(6):1253-62. Epub 2007 Mar 20. [PubMed:17374880 ]
- Lingwood D, Simons K: Lipid rafts as a membrane-organizing principle. Science. 2010 Jan 1;327(5961):46-50. doi: 10.1126/science.1174621. [PubMed:20044567 ]
- Gunstone, Frank D., John L. Harwood, and Albert J. Dijkstra (2007). The lipid handbook with CD-ROM. CRC Press.
|
|---|